Literature DB >> 15582466

Structure-activity relationships for inhibition of human cholinesterases by alkyl amide phenothiazine derivatives.

Sultan Darvesh1, Robert S McDonald, Andrea Penwell, Sarah Conrad, Katherine V Darvesh, Diane Mataija, Geraldine Gomez, Angela Caines, Ryan Walsh, Earl Martin.   

Abstract

Several lines of evidence indicate that inhibition of butyrylcholinesterase (BuChE) is important in the treatment of certain dementias. Further testing of this concept requires inhibitors that are both BuChE-selective and robust. N-alkyl derivatives (2, 3, 4) of phenothiazine (1) have previously been found to inhibit only BuChE in a mechanism involving pi-pi interaction between the phenothiazine tricyclic ring system and aromatic residues in the active site gorge. To explore features of phenothiazines that affect the selectivity and potency of BuChE inhibition, a series of N-carbonyl derivatives (5-25) was synthesized and examined for the ability to inhibit cholinesterases. Some of the synthesized derivatives also inhibited AChE through a different mechanism involving carbonyl interaction within the active site gorge. Binding of these derivatives takes place within the gorge, since this inhibition disappears when the molecular volume of the derivative exceeds the estimated active site gorge volume of this enzyme. In contrast, BuChE, with a much larger active site gorge, exhibited inhibition that increased directly with the molecular volumes of the derivatives. This study describes two distinct mechanisms for binding phenothiazine amide derivatives to BuChE and AChE. Molecular volume was found to be an important parameter for BuChE-specific inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582466     DOI: 10.1016/j.bmc.2004.09.059

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

Review 2.  New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

Authors:  Nigel H Greig; Marcella Reale; Ada M Tata
Journal:  Recent Pat CNS Drug Discov       Date:  2013-08

3.  New therapeutic approaches and novel alternatives for organophosphate toxicity.

Authors:  Francine S Katz; Stevan Pecic; Laura Schneider; Zhengxiang Zhu; Ashley Hastings; Michal Luzac; Joanne Macdonald; Donald W Landry; Milan N Stojanovic
Journal:  Toxicol Lett       Date:  2018-03-31       Impact factor: 4.372

4.  Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study.

Authors:  Terrone L Rosenberry; Xavier Brazzolotto; Ian R Macdonald; Marielle Wandhammer; Marie Trovaslet-Leroy; Sultan Darvesh; Florian Nachon
Journal:  Molecules       Date:  2017-11-29       Impact factor: 4.411

5.  Synthesis of Novel Chalcone-Based Phenothiazine Derivatives as Antioxidant and Anticancer Agents.

Authors:  Nourah A Al Zahrani; Reda M El-Shishtawy; Mahmoud M Elaasser; Abdullah M Asiri
Journal:  Molecules       Date:  2020-10-06       Impact factor: 4.411

6.  Probing the peripheral site of human butyrylcholinesterase.

Authors:  Ian R Macdonald; Earl Martin; Terrone L Rosenberry; Sultan Darvesh
Journal:  Biochemistry       Date:  2012-08-27       Impact factor: 3.162

7.  Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease.

Authors:  Galina F Makhaeva; Sofya V Lushchekina; Natalia P Boltneva; Vladimir B Sokolov; Vladimir V Grigoriev; Olga G Serebryakova; Ekaterina A Vikhareva; Alexey Yu Aksinenko; George E Barreto; Gjumrakch Aliev; Sergey O Bachurin
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.